Thomas Turalski
Director/Board Member presso RYVU THERAPEUTICS S.A.
Patrimonio netto: 278 232 $ in data 31/03/2024
Profilo
Mr. Thomas Turalski is on the Board of Directors at Ryvu Therapeutics SA. Mr. Turalski was previously employed as a Senior Analyst by Perceptive Advisors LLC, a Senior Analyst by Perceptive Advisors LLC, a Member by Acerta Pharma BV, and a Principal by Exis Capital Management, Inc. He received his undergraduate degree from The Trustees of Columbia University in The City of New York.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
RYVU THERAPEUTICS SA
0.09% | 31/12/2022 | 20 100 ( 0.09% ) | 278 232 $ | 31/03/2024 |
Posizioni attive di Thomas Turalski
Società | Posizione | Inizio |
---|---|---|
RYVU THERAPEUTICS S.A. | Director/Board Member | - |
Precedenti posizioni note di Thomas Turalski
Società | Posizione | Fine |
---|---|---|
Exis Capital Management, Inc.
Exis Capital Management, Inc. Investment ManagersFinance Founded in 1998 by Adam Sender, Exis Capital Management, Inc. is a hedge fund manager located in New York City | Corporate Officer/Principal | 31/12/2007 |
Perceptive Advisors LLC
Perceptive Advisors LLC Investment ManagersFinance Perceptive Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Joseph “Joe” Edelman in 1999. provides investment advice to private funds, separate accounts, and co-investment vehicles. Investors in the client accounts and co-investment vehicles consist primarily of institutional investors, financial institutions, other investment funds, and high-net-worth individuals. | Analyst-Equity | 01/01/2005 |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | Corporate Officer/Principal | - |
Perceptive Advisors LLC
Perceptive Advisors LLC Investment ManagersFinance Perceptive Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Joseph “Joe” Edelman in 1999. provides investment advice to private funds, separate accounts, and co-investment vehicles. Investors in the client accounts and co-investment vehicles consist primarily of institutional investors, financial institutions, other investment funds, and high-net-worth individuals. | Analyst-Equity | - |
Formazione di Thomas Turalski
The Trustees of Columbia University in The City of New York | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
RYVU THERAPEUTICS S.A. | Health Technology |
Aziende private | 3 |
---|---|
Exis Capital Management, Inc.
Exis Capital Management, Inc. Investment ManagersFinance Founded in 1998 by Adam Sender, Exis Capital Management, Inc. is a hedge fund manager located in New York City | Finance |
Perceptive Advisors LLC
Perceptive Advisors LLC Investment ManagersFinance Perceptive Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Joseph “Joe” Edelman in 1999. provides investment advice to private funds, separate accounts, and co-investment vehicles. Investors in the client accounts and co-investment vehicles consist primarily of institutional investors, financial institutions, other investment funds, and high-net-worth individuals. | Finance |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | Health Technology |
- Borsa valori
- Insiders
- Thomas Turalski